Compare LKFN & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | DMRA |
|---|---|---|
| Founded | 1872 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2009 | 2020 |
| Metric | LKFN | DMRA |
|---|---|---|
| Price | $60.71 | $20.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $67.00 | $43.00 |
| AVG Volume (30 Days) | 147.9K | ★ 308.5K |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $985,000.00 | N/A |
| Revenue This Year | $15.50 | N/A |
| Revenue Next Year | $5.51 | N/A |
| P/E Ratio | $59.45 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $54.36 | $16.50 |
| 52 Week High | $69.38 | $28.76 |
| Indicator | LKFN | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.92 | 33.97 |
| Support Level | $60.51 | N/A |
| Resistance Level | $60.94 | $27.70 |
| Average True Range (ATR) | 1.39 | 1.97 |
| MACD | 0.18 | -0.30 |
| Stochastic Oscillator | 56.20 | 21.42 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare. The company's revenue is derived from the business of banking.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.